Jun. 6 at 10:35 AM
$CRDL One thing often overlooked in recurrent pericarditis is the current treatment landscape.
Rilonacept is an excellent drug, but it comes with limitations:
• Around
$250,000 per year.
• Weekly injections.
• Immune-modulating therapy.
• Higher infection risk.
• Common injection site reactions.
• Many patients remain on treatment for years.
Most importantly, relapses after discontinuation are common, which is one reason many patients stay on therapy long-term.
That’s why there is still room for additional options. If CardiolRx can prevent recurrences while maintaining its encouraging safety profile, it could fill an important gap between conventional therapies and expensive biologics.
The goal isn’t to replace rilonacept, but to give physicians and patients another effective, potentially oral and more accessible option.
That’s why the MAVERIC Phase 3 trial matters.
